BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19087134)

  • 1. Update on therapeutic options in Waldenström macroglobulinemia.
    Leleu X; Gay J; Roccaro AM; Moreau AS; Poulain S; Dulery R; Champs BB; Robu D; Ghobrial IM
    Eur J Haematol; 2009 Jan; 82(1):1-12. PubMed ID: 19087134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Waldenstrom macroglobulinemia.
    Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
    Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Waldenström's macroglobulinemia].
    Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
    Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waldenström macroglobulinemia.
    Vijay A; Gertz MA
    Blood; 2007 Jun; 109(12):5096-103. PubMed ID: 17303694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
    Neparidze N; Dhodapkar MV
    Clin Adv Hematol Oncol; 2009 Oct; 7(10):677-81, 687-90. PubMed ID: 20040909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment options for Waldenström macroglobulinemia.
    Vijay A; Gertz MA
    Clin Lymphoma Myeloma; 2008 Aug; 8(4):219-29. PubMed ID: 18765309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waldenström macroglobulinemia.
    Kasi PM; Ansell SM; Gertz MA
    Clin Adv Hematol Oncol; 2015 Jan; 13(1):56-66. PubMed ID: 25679974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Therapeutic Approaches for Waldenstrom Macroglobulinemia.
    Stedman J; Roccaro A; Leleu X; Ghobrial IM
    Drugs Future; 2010 Jan; 35(1):53-58. PubMed ID: 21869855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waldenström macroglobulinaemia.
    Fonseca R; Hayman S
    Br J Haematol; 2007 Sep; 138(6):700-20. PubMed ID: 17672883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Waldenström macroglobulinemia: from biology to treatment.
    Sahin I; Leblebjian H; Treon SP; Ghobrial IM
    Expert Rev Hematol; 2014 Feb; 7(1):157-68. PubMed ID: 24405328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies in Waldenström macroglobulinemia.
    Burwick N; Roccaro AM; Leleu X; Ghobrial IM
    Curr Opin Investig Drugs; 2008 Jun; 9(6):631-7. PubMed ID: 18516762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2019 Feb; 94(2):266-276. PubMed ID: 30328142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in the treatment of Waldenström's macroglobulinemia.
    Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
    Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib and Waldenstrom's macroglobulinemia.
    Pascal L; Gay J; Willekens C; Wemeau M; Balkaran S; Robu D; Roccaro A; Morel P; Ghobrial I; Leleu X
    Expert Opin Pharmacother; 2009 Apr; 10(5):909-16. PubMed ID: 19351237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waldenström macroglobulinaemia.
    Ghobrial IM; Gertz MA; Fonseca R
    Lancet Oncol; 2003 Nov; 4(11):679-85. PubMed ID: 14602248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
    J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current options to manage Waldenström's macroglobulinemia.
    Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.
    Treon SP; Gertz MA; Dimopoulos M; Anagnostopoulos A; Blade J; Branagan AR; Garcia-Sanz R; Johnson S; Kimby E; Leblond V; Fermand JP; Maloney DG; Merlini G; Morel P; Morra E; Nichols G; Ocio EM; Owen R; Stone MJ
    Blood; 2006 May; 107(9):3442-6. PubMed ID: 16410453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.